Literature DB >> 8864524

The role of TNF-alpha in fever: opposing actions of human and murine TNF-alpha and interactions with IL-beta in the rat.

A Stefferl1, S J Hopkins, N J Rothwell, G N Luheshi.   

Abstract

1. The role of tumour necrosis factor-alpha (TNF-alpha) in fever is controversial. Some studies have indicated that TNF-alpha acts as a cryogen to inhibit fever, while others suggest that TNF-alpha is an endogenous pyrogen which mediates fever. The majority of studies in experimental animals supporting a cryogenic action have been conducted using human (h)TNF-alpha, which has been shown to bind only to one (p55) of the two TNF-alpha receptors in rodents. 2. The aim of the present investigation was to study the role of TNF-alpha in fever by comparing effects of hTNF-alpha, which binds only to the p55 receptor, with those of murine (m) TNF-alpha, which binds to both p55 and p75 TNF-alpha receptors, and to investigate the relationship between TNF-alpha and interleukin-1 (IL-1), an important endogenous pyrogen. 3. Injection of hTNF-alpha (0.3-10 micrograms kg-1, i.p.) had no effect on core temperature in conscious rats (measured by remote radiotelemetry), whereas mTNF-alpha (3 micrograms kg-1) induced fever which was maximal 1 h after the injection (38.2 +/- 0.2 degrees C compared to 37.3 +/- 0.1 degrees C in controls). Intracerebroventricular (i.c.v.) administration of either form of TNF-alpha elicited dose-dependent fever at doses higher than 0.12 microgram kg-1. 4. Peripheral injection of hIL-1 beta (1 microgram kg-1) resulted in fever (38.3 +/- 0.2 degree C compared to 37.2 +/- 0.1 degrees C in controls at 2 h), which was significantly attenuated (P < 0.01) by co-administration of a sub-pyrogenic dose of hTNF-alpha (1 microgram kg-1), but was unaffected by co-administration of mTNF-alpha (0.1 or 0.3 microgram kg-1, i.p.). In contrast, intracerebroventricular (i.c.v.) co-administration of a sub-pyrogenic dose (0.12 microgram kg-1) of hTNF-alpha did not attenuate fever induced by intraperitoneal (i.p.) injection of IL-1 beta, and sub-pyrogenic dose (0.12 microgram kg-1, i.c.v.) of mTNF-alpha significantly prolonged the febrile response to IL-1 beta. Pretreatment of animals with anti-TNF-alpha antiserum (i.c.v.) did not affect the febrile response to systemic IL-1 beta. 5. Animals injected i.p. with a pyrogenic dose of mTNF-alpha developed fever (38.2 +/- 0.2 degrees C compared to 37.3 +/- 0.1 degrees C in controls 2 h after the injection) that was completely abolished by peripheral administration of IL-1ra (2 mg kg-1, P < 0.001), while i.c.v. administration of IL-1ra (400 micrograms/rat) did not affect mTNF-alpha-induced fever. 6. These data indicate that endogenous TNF-alpha is probably a pyrogen and that previous results suggesting cryogenic actions of TNF-alpha resulted from the use of a heterologous protein in the rat. The markedly contrasting effects of mTNF-alpha and TNF-alpha could result from different interactions with the two TNF-alpha receptor subtypes. The data also suggest that fever induced by exogenous TNF-alpha is mediated via release of IL-1 beta in peripheral tissues, but not in the brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864524      PMCID: PMC1909906          DOI: 10.1111/j.1476-5381.1996.tb15625.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.

Authors:  A A Jakubowski; E S Casper; J L Gabrilove; M A Templeton; S A Sherwin; H F Oettgen
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

2.  Role of interleukin 6 in fever in rats.

Authors:  L G LeMay; A J Vander; M J Kluger
Journal:  Am J Physiol       Date:  1990-03

3.  Tumor necrosis factor and interleukin-1 beta: suppression of food intake by direct action in the central nervous system.

Authors:  C R Plata-Salamán; Y Oomura; Y Kai
Journal:  Brain Res       Date:  1988-05-10       Impact factor: 3.252

4.  Central effects of TNF alpha on thermogenesis and fever in the rat.

Authors:  N J Rothwell
Journal:  Biosci Rep       Date:  1988-08       Impact factor: 3.840

5.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever.

Authors:  J G Cannon; R G Tompkins; J A Gelfand; H R Michie; G G Stanford; J W van der Meer; S Endres; G Lonnemann; J Corsetti; B Chernow
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

6.  Recombinant human tumor necrosis factor causes long-lasting and prostaglandin-mediated fever, with little tolerance, in rabbits.

Authors:  H Nakamura; Y Seto; S Motoyoshi; T Kadokawa; N Sunahara
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

7.  Characteristics of fever and acute-phase response induced in rabbits by IL-1 and TNF.

Authors:  A Morimoto; Y Sakata; T Watanabe; N Murakami
Journal:  Am J Physiol       Date:  1989-01

8.  Antiserum against tumor necrosis factor enhances lipopolysaccharide fever in rats.

Authors:  N C Long; S L Kunkel; A J Vander; M J Kluger
Journal:  Am J Physiol       Date:  1990-02

9.  Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.

Authors:  H R Michie; D R Spriggs; K R Manogue; M L Sherman; A Revhaug; S T O'Dwyer; K Arthur; C A Dinarello; A Cerami; S M Wolff
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  12 in total

1.  An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.

Authors:  Andrew Stamm; Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

2.  Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist.

Authors:  J M Cunha; F Q Cunha; S Poole; S H Ferreira
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4.

Authors:  F Q Cunha; S Poole; B B Lorenzetti; F H Veiga; S H Ferreira
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

4.  Neutralization of pyrogen-induced tumour necrosis factor by its type 1 soluble receptor in guinea-pigs: effects on fever and interleukin-6 release.

Authors:  J Roth; D Martin; B Störr; E Zeisberger
Journal:  J Physiol       Date:  1998-05-15       Impact factor: 5.182

5.  Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain.

Authors:  T Cartmell; T Southgate; G S Rees; M G Castro; P R Lowenstein; G N Luheshi
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

6.  Inhibition of tumor necrosis factor-alpha action within the CNS markedly reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats.

Authors:  A V Turnbull; F J Pitossi; J J Lebrun; S Lee; J C Meltzer; D M Nance; A del Rey; H O Besedovsky; C Rivier
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

8.  Severe erythema multiforme-type drug eruption controlled by tumor necrosis factor-α antagonist: A case study.

Authors:  Xin Ling; Xin Shi; Lingling Chen
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

9.  TNFα Triggers an Augmented Inflammatory Response in Brain Neurons from Dahl Salt-Sensitive Rats Compared with Normal Sprague Dawley Rats.

Authors:  Huanjia Gao; Jeremy Bigalke; Enshe Jiang; Yuanyuan Fan; Bojun Chen; Qing-Hui Chen; Zhiying Shan
Journal:  Cell Mol Neurobiol       Date:  2021-02-24       Impact factor: 4.231

10.  PKR deficiency alters E. coli-induced sickness behaviors but does not exacerbate neuroimmune responses or bacterial load.

Authors:  David Chun-Hei Poon; Yuen-Shan Ho; Ran You; Hei-Long Tse; Kin Chiu; Raymond Chuen-Chung Chang
Journal:  J Neuroinflammation       Date:  2015-11-19       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.